 |
|
| Updated Nov. 9, 2009 |
|
||||||||
 |
|
 |
|
 |
|
 |
|
 |
|
||||||||
| |
|
FDA Approves Invega Sustenna for Acute and Maintenance Treatment of Schizophrenia
ISSUE: AUGUST, 2009 The FDA has approved Invega Sustenna (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. read more & comment | |
|
Now Available on CMEZone
ISSUE: AUGUST, 2009 “Improving Evidence-Based, Individualized Care of Patients with Schizophrenia,” a CME monograph, is now available (for review) on CMEZone.com; enter the project number “SR08124” in the keyword field for viewing. Note also that the original monograph misattributed Figure 1; the correct attribution, which has been corrected on CMEZone.com, is: Adapted with permission from Stahl’s Essential Pharmacology, 3rd Edition, Cambridge University Press, 2008 © Neuroscience Education Institute read more & comment | |
|
Study: Treating Aggression and Cognition in Schizophrenia Extremely Difficul
ISSUE: NOVEMBER, 2008 Treatment for patients with schizophrenia who exhibit violent behavior may entail a trade-off between reduced aggression and improved cognition, according to results from a new double-blind study. read more & comment | |
|
Second-generation Antipsychotics Effective and Safe for Acute Agitation
ISSUE: NOVEMBER, 2008 Second-generation antipsychotics delivered intramuscularly are as effective as first-generation antipsychotics for treating the acutely agitated patient, without producing as many adverse events. read more & comment | |
|
Study Compares Olanzapine, Clozapine For Early-Onset Schizophrenia
ISSUE: OCTOBER, 2008 A double-blind, randomized study of 39 children and adolescents with early-onset, refractory schizophrenia has revealed that two-thirds of these patients experience a clinical response to clozapine treatment, compared with only one-third who respond to high doses of olanzapine. read more & comment | |
|
Study: Atypical Antipsychotic Improves Social Relationships Of Patients With Schizophrenia
ISSUE: OCTOBER, 2008 The atypical antipsychotic ziprasidone may improve vocational and social performance among people with schizophrenia more so than the conventional agent haloperidol. read more & comment | |
|
Large Study Used To Probe Ethnic Differences In Responses to Antipsychotics
ISSUE: SEPTEMBER, 2008 An examination of the CATIE trial results has found significantly lower rates of extrapyramidal symptoms and akathisia at the end of the study among blacks than whites or Hispanics, but no significant differences in time to treatment discontinuation or PANSS total scores. read more & comment | |
|
Specialized Medication Groups Best for Patients With Schizophrenia, OSA
ISSUE: JULY, 2008 Quality of care, patient satisfaction and overall well-being improve when mentally ill patients with obstructive sleep apnea are assigned to a specialized medication group that focuses on their physical ailment. read more & comment |
| home | about us | advertise | contact | publications |